Integra LifeSciences beats Q2 estimates with $0.56 adjusted EPS on $419M revenue

Integra LifeSciences posted adjusted earnings that topped Wall Street estimates by nearly 16 percent in the second quarter, as the medical device maker advanced the planned relaunch of its SurgiMend product.

"Our second-quarter performance reflects meaningful progress on our most important priorities," said Stuart Essig, Chairman and CEO of Integra LifeSciences. "We are improving supply reliability, advancing quality, and returning products to market with discipline."

Revenue of $418.8 million was flat year over year but matched the $417.7 million consensus. Adjusted earnings per share of $0.56 exceeded the average analyst estimate of $0.48, rising 24 percent from $0.45 a year earlier. Adjusted EBITDA reached $78.4 million, or 18.7 percent of revenue, beating the $73.5 million consensus.

The Braintree, Massachusetts, facility is now producing and ramping to support the SurgiMend relaunch planned for the fourth quarter, a product that could help reverse the 1.9 percent decline in Integra's tissue reconstruction segment. The company maintained its full-year adjusted EPS guidance of $2.40 to $2.50 but trimmed its revenue outlook to $1.654 billion to $1.695 billion, citing a stronger U.S. dollar.

The Specialty Surgery segment, which accounts for about 70 percent of total revenue, grew 1.7 percent to $309.3 million, driven by 2 percent growth in neurosurgery and 3.3 percent growth in instruments. The Tissue Reconstruction segment, which includes wound care and private-label products, fell 1.9 percent to $109.5 million, with wound reconstruction solutions declining 4.1 percent.

Integra's adjusted gross margin improved to 61.3 percent from 60.7 percent a year ago, reflecting cost discipline and the benefits of bringing manufacturing in-house at Braintree. However, its GAAP operating margin contracted to 4.6 percent from 7.9 percent, weighed down by $9.9 million in Braintree transition costs and $7.5 million in structural optimization charges.

The company generated $10.5 million in free cash flow during the quarter, a sharp improvement from negative $11.2 million in the same period last year. Net debt stood at $1.6 billion, with a leverage ratio of 4.1 times, as Integra continues to prioritize balance sheet deleveraging.

Integra shares, which trade at roughly 8 times forward earnings based on the midpoint of full-year guidance, were flat at $19.75 after the report. The stock has fallen about 40 percent over the past year, reflecting persistent concerns about supply disruptions and quality remediation at its Braintree facility. The SurgiMend relaunch represents a potential catalyst, but the company's 4.1 times leverage ratio and flat organic revenue leave limited margin for error. Rivals such as Johnson & Johnson's Ethicon unit and Medtronic dominate the soft tissue repair market, making market share gains an uphill battle.

This article is for informational purposes only and does not constitute investment advice.